
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc has shown strong revenue performance, reporting $98.6 million in revenue for the latest quarter, which represents a year-over-year growth of approximately 13%, driven by robust contributions from both its wound and surgical product portfolios. The company's wound portfolio experienced a 12% year-over-year increase, while the surgical segment saw a more pronounced growth of 15%, highlighting the overall strengthening of its surgical business. Additionally, the upward revision of the 2025 revenue estimate to $387.3 million underscores confidence in ongoing sales momentum and operational performance.
Bears say
MiMedx Group Inc experienced a decline in gross margin, decreasing from approximately 83% to 81% in 2Q25, primarily attributed to production variances and changes in product mix, which may signal potential operational inefficiencies. The company's long-term guidance suggests a target of low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin exceeding 20%, but these goals appear optimistic given the recent margin decline. Furthermore, the company's reliance on reimbursement rates from CMS poses a vulnerability, as any adverse changes could significantly impact its revenue and overall business performance.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares